Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 1/20 | 0.55 |
| ▸ | CCR5 | P51681 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6777403 | 0.89 | TACR2 (0.56) | TACR2CCR5OPRM1OPRD1OPRK1 | |
| SCHEMBL6780052 | 0.87 | CCR5 (0.62) | CCR5OPRM1OPRD1OPRK1 | |
| SCHEMBL6780430 | 0.85 | CCR5 (0.49) | CCR5OPRM1OPRD1OPRK1CYP1A2 | |
| SCHEMBL6778397 | 0.85 | DRD2 (0.50) | TACR2CCR5OPRM1OPRK1DRD2 | |
| SCHEMBL6774082 | 0.83 | TACR2 (0.56) | TACR2OPRM1OPRD1OPRK1DRD2 | |
| SCHEMBL6779960 | 0.81 | CYP3A4 (0.51) | TACR2CCR5OPRM1OPRD1OPRK1 | |
| SCHEMBL6775075 | 0.81 | TACR2 (0.49) | TACR2CCR5OPRM1OPRD1 | |
| SCHEMBL6774420 | 0.79 | CCR5 (0.47) | CCR5OPRM1OPRD1OPRK1CYP1A2 | |
| SCHEMBL6779973 | 0.79 | OPRM1 (0.59) | TACR2OPRM1OPRD1OPRK1DRD2 | |
| SCHEMBL5858616 | 0.78 | DRD2 (0.69) | TACR2CCR5OPRM1DRD2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6790854-B2 | TREATMENT OF DEPRESSION, EPILEPSY AND PARKINSON'S ISEASE, ANALGESICS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030176693-A1 | Diphenylalkylamine derivatives useful as opioid receptor agonists | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1277737-A1 | DIPHENYLALKYLAMINE DERIVATIVES USEFUL AS OPIOID DELTA RECEPTOR AGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176693-A1 | Diphenylalkylamine derivatives useful as opioid receptor agonists | OPRM1, OPRK1, OPRL1 | TACR2 50/4885CCR5 272/4885OPRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.